Success Metrics

Clinical Success Rate

90.0%

Based on 9 completed trials

Completion Rate

90%(9/10)

Active Trials

0(0%)

Results Posted

89%(8 trials)

Terminated

1(10%)

Phase Distribution

Ph phase_3

70%

Ph phase_1

20%

Ph phase_2

10%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution10 total trials

Phase 1Safety & dosage

2(20.0%)

Phase 2Efficacy & side effects

1(10.0%)

Phase 3Large-scale testing

7(70.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(9)

Terminated(1)

Detailed Status

Completed9

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

90.0%

Most Advanced

Phase 3

Trials by Phase

Phase 12 (20.0%)

Phase 21 (10.0%)

Phase 37 (70.0%)

Trials by Status

completed990%

terminated110%

Recent Activity

0 active trials

Showing 5 of 10

completedphase_3

An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023)

NCT00094757

completedphase_3

MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)

NCT00532935

completedphase_3

A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)

NCT01076075

completedphase_3

MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED)

NCT00372060

completedphase_1

Sitagliptin and Pioglitazone Mechanism of Action Study in Type 2 Diabetes Mellitus (0431-061)

NCT00511108

View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials

NCT00094757Phase 3

An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023)

Completed

NCT00532935Phase 3

MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)

Completed

NCT01076075Phase 3

A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)

Completed

NCT00372060Phase 3

MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED)

Completed

NCT00511108Phase 1

Sitagliptin and Pioglitazone Mechanism of Action Study in Type 2 Diabetes Mellitus (0431-061)

Completed

NCT00541450Phase 3

A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)

Completed

NCT00086502Phase 3

Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus

Completed

NCT01115712Phase 1

Effects of Pioglitazone on Insulin Sensitivity in Healthy Overweight and Obese Males (MK-0000-170)

Completed

NCT00106704Phase 3

Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035)

Completed

NCT00543959Phase 2

Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)